Bullish & Foolish
Full LABT fundamentals All 466 on the Survival Watch

LABTLAKEWOOD-AMEDEX BIOTHERAPEUTICS INC.

Is Lakewood-Amedex Biotherapeutics struggling financially?

Yes, by its own account. Lakewood-Amedex Biotherapeutics told the SEC on 22 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

30/100

Fragile

Sector
Biotech/Pharma
Market cap
$5.3M
Source filing
10-Q 22 May 2026
Balance sheet
30 Jun 2026

Cash runway

Not estimable

The latest filings do not carry the cash or cash-flow lines needed to estimate a runway. Publishing a number here would mean inventing one.

What it reported

Cash and short-term investments

$4.6M

What Lakewood-Amedex Biotherapeutics told the SEC

…incurred losses from operations and expects to continue to generate negative cash flows as the Company implements its business plan. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. Subsequent to March 31, 2026, on April 21, 2026, the Company completed a private offering of Series C…

LAKEWOOD-AMEDEX BIOTHERAPEUTICS INC., Form 10-Q, filed 22 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 52.9% share-count increase The company issued stock. Each share now owns 34.6% less of the business than a year ago, before any change in the price.

Other Biotech/Pharma companies that filed the doubt